Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07610538 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells

Study acronym: Leuk-ALIVE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.
Trial Details
NCT Number NCT07610538
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: Royal Papworth Hospital
Conditions
(from sponsor)		 Coronary Artery Disease, Myocardial Infarction (MI), CABG
Related terms Coronary Artery Disease, Myocardial Infarction
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov